Orgenesis Inc (ORGS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orgenesis Inc (ORGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9419
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orgenesis Inc (Orgenesis) is a biopharmaceutical company that focuses on the development and manufacturing of regenerative cellular therapy and medicine for the treatment of insulin-dependent diabetes patients. The company, through its subsidiaries, offers contract development and manufacturing, and proprietary cell therapy development. It also provides GMP manufacturing, process development, quality management and assay development, and other services. Orgenesis offers cell therapies for autoimmune, oncologic, neurologic and orthopedic diseases. The company utilizes its proprietary technology to reprogram human liver cells into glucose-responsive insulin-producing cells to provide a practical cure for insulin-dependent diabetes. Orgenesis is headquartered in Germantown, Maryland, the US.

Orgenesis Inc (ORGS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orgenesis Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Orgenesis Raises USD1.2 Million in Venture Financing 12
Orgenesis Raises USD5.3 Million in Financing Round 13
Partnerships 14
Zelluna Immunotherapy Enters into Partnership with Masthercell 14
CRISPR Therapeutics Enters into Agreement with MaSTherCell 15
Les Laboratoires Servier and Masthercell Enter into Agreement 16
Orgenesis Forms Joint Venture with Atvio Biotech 17
Orgenesis Forms Joint Venture with CureCell 18
Orgenesis Enters into Agreement with Biosequel 19
Orgenesis Enters into Research Agreement with GSRAC 20
Masthercell Forms Joint Venture with Kalon 21
Licensing Agreements 22
Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22
Orgenesis Enters into Licensing Agreement with Immugenyx 23
HekaBio Enters into Licensing Agreement with Orgenesis 24
Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25
Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26
Equity Offering 27
Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27
Masthercell Raises USD5.9 Million in Equity Financing 28
Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29
Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30
Orgenesis Raises Funds through Private Placement of Shares and Warrants 31
Orgenesis Raises Funds through Private Placement of Shares and Warrants 32
Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33
Orgenesis Announces Private Placement Of Shares For US$3 Million 34
Orgenesis Completes Private Placement Of Units For US$1.3 Million 35
Acquisition 36
Orgenesis Acquires MaSTherCell 36
Orgenesis Inc – Key Competitors 37
Orgenesis Inc – Key Employees 38
Orgenesis Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Apr 19, 2018: Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018 40
Government and Public Interest 42
Feb 13, 2017: Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program 42
Other Significant Developments 43
Mar 08, 2017: Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Orgenesis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orgenesis Raises USD1.2 Million in Venture Financing 12
Orgenesis Raises USD5.3 Million in Financing Round 13
Zelluna Immunotherapy Enters into Partnership with Masthercell 14
CRISPR Therapeutics Enters into Agreement with MaSTherCell 15
Les Laboratoires Servier and Masthercell Enter into Agreement 16
Orgenesis Forms Joint Venture with Atvio Biotech 17
Orgenesis Forms Joint Venture with CureCell 18
Orgenesis Enters into Agreement with Biosequel 19
Orgenesis Enters into Research Agreement with GSRAC 20
Masthercell Forms Joint Venture with Kalon 21
Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22
Orgenesis Enters into Licensing Agreement with Immugenyx 23
HekaBio Enters into Licensing Agreement with Orgenesis 24
Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25
Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26
Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27
Masthercell Raises USD5.9 Million in Equity Financing 28
Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29
Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30
Orgenesis Raises Funds through Private Placement of Shares and Warrants 31
Orgenesis Raises Funds through Private Placement of Shares and Warrants 32
Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33
Orgenesis Announces Private Placement Of Shares For US$3 Million 34
Orgenesis Completes Private Placement Of Units For US$1.3 Million 35
Orgenesis Acquires MaSTherCell 36
Orgenesis Inc, Key Competitors 37
Orgenesis Inc, Key Employees 38
Orgenesis Inc, Subsidiaries 39

List of Figures
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Orgenesis Inc (ORGS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genting Bhd (GENTING):企業の財務・戦略的SWOT分析
    Genting Bhd (GENTING) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NeuroMetrix Inc (NURO):企業の財務・戦略的SWOT分析
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • Rafael Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), formerly Cornerstone Pharmaceuticals Inc, is a clinical-stage, metabolic oncology therapeutics company, which focuses to develop and commercialize cancer metabolism based drugs. The company’s lead drug candidate CPI-613 is designed to targ …
  • Urban One Inc (UONEK):企業の財務・戦略的SWOT分析
    Urban One Inc (UONEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • A. Schulman Inc (SHLM):企業の財務・戦略的SWOT分析
    A. Schulman Inc (SHLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sinovac Biotech Ltd (SVA):企業の財務・戦略的SWOT分析
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, a an inactivated hepatitis A vaccine; bilive, a combined inactivated hepatitis A and B vaccine; anflu, a split viron influenz …
  • Paranta Biosciences Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Paranta Biosciences Ltd (Paranta Biosciences) is a clinical stage biopharmaceutical company which develops follistatin-based bio-therapeutic for the treatment of inflammatory and fibrotic diseases. The company’s lead product candidate PB01, a recombinant human follistatin-288 is under phase …
  • Marriott Vacations Worldwide Corp:企業の戦略・SWOT・財務分析
    Marriott Vacations Worldwide Corp - Strategy, SWOT and Corporate Finance Report Summary Marriott Vacations Worldwide Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • ESSA Pharma Inc (EPI):企業の財務・戦略的SWOT分析
    Summary Essa Pharma Inc (Essa Pharma) is a drug developer that offers oncology therapeutics. The company develops EPI-506, disrupts androgen receptor transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen r …
  • Neoen SAS:電力:M&Aディール及び事業提携情報
    Summary Neoen SAS (Neoen), a subsidiary of Direct Energie SA, is an independent producer of sustainable energy provider. The company generates power from solar, wind and biomass. It specializes in the development, finance, construction and operation of green power plants such as wind farms, solar fa …
  • Biotec Pharmacon ASA (BIOTEC):医療機器:M&Aディール及び事業提携情報
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • International Standard Resources Holdings Ltd (91):石油・ガス:M&Aディール及び事業提携情報
    Summary International Standard Resources Holdings Ltd (International Standard Resources), formerly New Smart Energy Group Ltd is a diversified company. The company’s business activities include coalbed methane, treasury, and electronic components. Its coalbed methane project includes CBM project, wh …
  • Shanghai Pharmaceutical Co Ltd (601607):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic a …
  • Bone Therapeutics SA (BOTHE):医療機器:M&Aディール及び事業提携情報
    Summary Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. The company offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fracture …
  • FuelCell Energy Inc (FCEL):企業の財務・戦略的SWOT分析
    FuelCell Energy Inc (FCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • S-Oil Corporation Inc (010950):石油・ガス:M&Aディール及び事業提携情報
    Summary S-Oil Corporation Inc (S-Oil) is a service driven company that operates in the petroleum and petrochemical industry. The company imports and exports crude oil; as well as manufactures and sells oil refining products, petrochemical products and lube products. S-Oil also produces a wide range …
  • Qiagen Marseille SA-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • BioSyent Inc (RX):企業の財務・戦略的SWOT分析
    Summary BioSyent Inc (BioSyent), formerly Hedley Technologies Inc is a specialty pharmaceutical company that offers in-licensing or acquiring innovative pharmaceutical products and technologies to enhance human health. The company’s products include Aguettant System for pre-filled syringes, FeraMAX …
  • MITIE Group Plc (MTO):企業の財務・戦略的SWOT分析
    MITIE Group Plc (MTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Autoridad del Canal de Panama:企業の戦略的SWOT分析
    Autoridad del Canal de Panama - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆